<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970773</url>
  </required_header>
  <id_info>
    <org_study_id>2013-21</org_study_id>
    <nct_id>NCT02970773</nct_id>
  </id_info>
  <brief_title>Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury</brief_title>
  <acronym>rivaroxaban</acronym>
  <official_title>Prospective, Non-randomized, Open-label, Mono-centric, Cohort Study on the Absorption of Oral Rivaroxaban in Patients With a Cervical Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Paraplegic Centre Nottwil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Paraplegic Centre Nottwil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate the pharmacokinetic and -dynamic&#xD;
      properties of rivaroxaban after oral administration in cervical spinal cord injury (SCI)&#xD;
      individuals.&#xD;
&#xD;
      The secondary objective of this study is to determine the steady-state rivaroxaban activity&#xD;
      in cervical SCI individuals under long-term therapy.&#xD;
&#xD;
      Primary Objective In-house patients will be informed concerning the study and informed&#xD;
      consent will be collected.&#xD;
&#xD;
      During the screening day, in- / exclusion criteria will be assessed and a blood samples will&#xD;
      be taken for assessing haematology, clinical chemistry and coagulation parameters.&#xD;
      Furthermore, the evaluation day will be scheduled.&#xD;
&#xD;
      On the evaluation day, in- / exclusion criteria will be re-assessed. A venous catheter will&#xD;
      be introduced into a forearm or lower leg of each participant for the collection of blood at&#xD;
      the specified time points. Skin inspection for subcutaneous bleeding will be performed and&#xD;
      vital signs will be recorded. A blood sample will be taken for assessing haematology,&#xD;
      clinical chemistry and coagulation parameters.&#xD;
&#xD;
      Single administration of oral rivaroxaban in the form of XareltoÂ® 10mg tablets (Bayer&#xD;
      Schering Pharma, Berlin, Germany).&#xD;
&#xD;
      Rivaroxaban concentrations will be determined from plasma samples taken before, 30min after&#xD;
      and 1, 2, 3, 4, 5, 6, 8, 12, 24 hours after rivaroxaban administration. Rivaroxaban activity&#xD;
      will be determined from plasma samples taken before, 30min after and 1, 2, 3, 4, 5, 6, 8, 12,&#xD;
      24 hours after rivaroxaban administration using a factor Xa inhibition test and measuring&#xD;
      prothrombin time (PT) and activated partial thromboplastin time (aPTT).&#xD;
&#xD;
      Skin inspection for subcutaneous bleeding and measurements of vital signs will be performed&#xD;
      30min and 1, 2, 3, 4, 5, 6, 8, 12 and 24 hours after rivaroxaban administration.&#xD;
&#xD;
      Secondary Objective Patients under long-term rivaroxaban therapy will be recruited during&#xD;
      their annual check-up visit at the Swiss Paraplegic Centre. In- / exclusion criteria will be&#xD;
      assessed, and the patients will be informed concerning the study and informed consent will be&#xD;
      collected.&#xD;
&#xD;
      Blood samples will be taken for assessing haematology, clinical chemistry and coagulation&#xD;
      parameters, and skin inspection for subcutaneous bleeding and measurements of vital signs&#xD;
      will be performed.&#xD;
&#xD;
      A blood sample (4.3ml citrated venous blood) will be taken for assessing the primary and&#xD;
      secondary outcome parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    insufficient recruitment; sponsor-investigator has left the institution&#xD;
  </why_stopped>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Actual">December 7, 2018</completion_date>
  <primary_completion_date type="Actual">December 7, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rivaroxaban plasma level</measure>
    <time_frame>before drug administration and 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>inhibition of factor XII</measure>
    <time_frame>before drug administration and 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prothrombin time</measure>
    <time_frame>before drug administration and 30min, 1h, 2h, 3h, 4h, 5h, 6h, 8h, 12h and 24h after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Rivaroxaban Oral Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban Oral Tablet</intervention_name>
    <description>oral application of Xarelto</description>
    <arm_group_label>rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Motor complete tetraplegia for at least 3 months&#xD;
&#xD;
          -  Age from 18 to 74 years&#xD;
&#xD;
          -  Body mass index (BMI) from 18 to 35kg/m2&#xD;
&#xD;
          -  Informed consent as documented by signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any anti-coagulation therapy (apart from rivaroxaban for second objective)&#xD;
&#xD;
          -  Hypersensitivity or allergy to factor Xa inhibitors&#xD;
&#xD;
          -  Acute bacterial endocarditis&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Clinically relevant active bleeding&#xD;
&#xD;
          -  Gastrointestinal ulcer or tumor&#xD;
&#xD;
          -  Hepatic dysfunction with increased bleeding risk&#xD;
&#xD;
          -  Renal failure / patients undergoing dialysis&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
          -  Gastrectomy, biliopancreatic diversion, resection or re-routing of small intestines&#xD;
&#xD;
          -  Feeding tube&#xD;
&#xD;
          -  Recent blood donation&#xD;
&#xD;
          -  Abnormalities of laboratory values: alanine-aminotransferase (ALAT),&#xD;
             aspartate-aminotransferase (ASAT), gamma-glutamyl transferase (gammaGT), alkalic&#xD;
             phosphatase (AP), bilirubin, amylase, lipase, cystatin C, creatinine, white blood cell&#xD;
             count, haemoglobin, platelet count, prothrombin time, aPTT, fibrinogen, thrombin time,&#xD;
             factors II,V,VII and X&#xD;
&#xD;
          -  Use of therapeutic or recreational drugs influencing plasmatic coagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Felleiter, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Parapelgic Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss Paraplegic Centre Nottwil</name>
      <address>
        <city>Nottwil</city>
        <state>Lucerne</state>
        <zip>6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

